PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.\', \'Division of Intramural Research, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA.\', \'Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: chenchen@tjh.tjmu.edu.cn.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0163-7258(20)30158-310.1016/j.pharmthera.2020.107628
?:hasPublicationType
?:journal
  • Pharmacology & therapeutics
is ?:pmid of
?:pmid
?:pmid
  • 32653530
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all